Asia-Pacific Cancer Drugs Market Size and Forecast (2021 - 2031)

The Asia Pacific Cancer Drugs Market is projected to grow significantly, reaching an estimated US$ 99,289.8 million by 2031, up from US$ 38,552.1 million in 2024. This growth represents a compound annual growth rate (CAGR) of 14.5% from 2025 to 2031, driven by various factors including an aging population, lifestyle changes, and increased healthcare spending.

Executive Summary and Market Analysis

The cancer drugs market in the Asia Pacific region is divided into several key countries: China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The incidence of cancer is rising sharply in these nations, attributed to demographic shifts such as a rapidly aging population, longer life expectancy, and lifestyle factors including poor diet, smoking, and insufficient physical activity. In 2023, the region accounted for a substantial share of global cancer cases, with significant numbers of new diagnoses of breast, lung, colorectal, and stomach cancers.

Governments across the Asia Pacific are responding to this crisis by increasing healthcare budgets, providing incentives for biotechnology development, approving new cancer treatments, and integrating advanced therapies into national health insurance programs. Countries like China and India are particularly attractive for global investment due to lower research and development costs and large populations ready for clinical trials. Additionally, partnerships are emerging, such as Chinese firms licensing PD1/PDL1 drugs to Western companies, showcasing the region's competitive edge in the biotech sector.

Japan, South Korea, and Australia are noted for their robust regulatory frameworks that support precision oncology. South Korea is expediting access to CAR-T therapies and novel biologics, while Australia is enhancing its national screening programs and clinical infrastructure. The expansion of healthcare facilities and the availability of advanced treatment options are crucial drivers of market growth in this region. Furthermore, the rise of biosimilars is making cancer treatments more affordable, thereby increasing accessibility for patients across the Asia Pacific.

Strategic Insights

# Market Segmentation Analysis

The Asia Pacific Cancer Drugs Market can be segmented by therapy types, indications, and distribution channels:

• By Therapy Types: The market is categorized into Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, and Other Therapy Types. Targeted Therapy is expected to lead the market in 2024.
• By Indications: The market is divided into Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Cervical Cancer, Liver and Intrahepatic Bile Ducts Cancer, Thyroid Cancer, and Other Indications. The Other Indications segment is anticipated to dominate in 2024.
• By Distribution Channel: The market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Stores, with Hospital Pharmacies expected to hold the largest share in 2024.

Market Outlook

Governments in the Asia Pacific recognize the critical need for a robust cancer treatment landscape and are implementing policies to enhance access to effective therapies. Increased funding for cancer research and development from both governmental and private sectors has led to the emergence of innovative drugs and therapies. For instance, the Indian government allocated approximately US$ 12 billion in its 2025-2026 budget to the Ministry of Health and Family Welfare, which includes initiatives to establish 200 Day Care Cancer Centres in district hospitals by 2025-2026 as part of the National Programme for Prevention and Control of Cancer (NPCDCS).

These initiatives aim to make cancer treatments more accessible through favorable reimbursement policies and other healthcare initiatives, ensuring that patients receive adequate coverage for cancer therapeutics. With enhanced funding and resources, healthcare providers can offer a broader range of treatment options, improving patient outcomes and maintaining competitiveness in the market. The increased support from governments and private organizations for the development and utilization of cancer therapeutics fosters innovation, creating significant growth opportunities in the cancer drugs market.

Country Insights

The Asia Pacific Cancer Drugs Market is further analyzed by country, with China holding the largest market share in 2024. According to the World Health Organization (WHO), approximately 4.5 million new cancer cases and 3 million cancer-related deaths were reported in China in 2020. The WHO estimates that every minute, around seven individuals are diagnosed with cancer, and four succumb to the disease. The most prevalent cancers in China include lung, stomach, breast, thyroid, and leukemia.

Factors such as an aging population, lifestyle changes, urbanization, and high smoking rates are contributing to the increasing cancer incidence and chronic disease burden. A study published in 2020 indicated that the proportion of individuals aged 60 and above in China is expected to rise from 12.4% (168 million) in 2010 to 28% (402 million) by 2040, highlighting the growing vulnerability of older adults to cancer.

Company Profiles

Key players in the Asia Pacific Cancer Drugs Market include F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Co, Johnson & Johnson, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, and Eli Lilly and Co. These companies are pursuing various strategies such as market expansion, product innovation, and mergers and acquisitions to enhance their offerings and increase market share.